Can-Fite’s Namodenoson Shows Strong Safety Profile in Advanced Pancreatic Cancer Patients

Can-Fite BioPharma shares positive Phase 2a results for Namodenoson in treating advanced pancreatic cancer, highlighting its safety and potential for better survival outcomes in tough cases.